參考文獻(xiàn)/References:
[1] 世界中醫(yī)藥學(xué)會聯(lián)合會骨質(zhì)疏松專業(yè)委員會,上海中醫(yī)藥大學(xué)附屬龍華醫(yī)院,中日友好醫(yī)院,等.骨質(zhì)疏松性骨折中西醫(yī)結(jié)合診療專家共識[J].世界中醫(yī)藥,2023,18(7):895-900.
[2] 中華醫(yī)學(xué)會骨科學(xué)分會.骨質(zhì)疏松性骨折診療指南(2022年版)[J].中華骨科雜志,2022,42(22):1473-1491.
[3] 中華中醫(yī)藥學(xué)會.骨質(zhì)疏松性骨折中醫(yī)診療指南[J].中醫(yī)正骨,2023,35(1):1-9.
[4] 中華醫(yī)學(xué)會骨質(zhì)疏松和骨礦鹽疾病分會.原發(fā)性骨質(zhì)疏松癥診療指南(2022年版)[J].中國全科醫(yī)學(xué),2023,26(14):1671-1691.
[5] KNOPP-SIHOTA J A,NEWBURN-COOK C V,HOMIK J,et al.Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures:a systematic review and meta-analysis[J].Osteoporos Int,2012,23(1):17-38.
[6] LOUIE G H,TEKTONIDOU M G,CABAN-MARTINEZ A J,et al.Sleep disturbances in adults with arthritis:prevalence,mediators,and subgroups at greatest risk.Data from the 2007 National Health Interview Survey[J].Arthritis Care Res(Hoboken),2011,63(2):247-260.
[7] 中華醫(yī)學(xué)會骨科學(xué)分會青年骨質(zhì)疏松學(xué)組,中國醫(yī)師協(xié)會急救復(fù)蘇專業(yè)委員會創(chuàng)傷骨科與多發(fā)傷學(xué)組,上海市中西醫(yī)結(jié)合學(xué)會骨質(zhì)疏松專業(yè)委員會.中國骨質(zhì)疏松性骨折圍手術(shù)期處理專家共識(2018)[J].中國臨床醫(yī)學(xué),2018,25(5):860-866.
[8] 裴育,董進,李梅.維生素D與骨質(zhì)疏松癥[J].中華骨質(zhì)疏松和骨礦鹽疾病雜志,2018,11(1):44-50.
[9] 王林,李春霖.鈣劑和維生素D在老年骨質(zhì)疏松癥中的應(yīng)用[J].中國臨床保健雜志,2022,25(1):30-33.
[10] WIMALAWANSA S J.Vitamin D deficiency:effects on oxidative stress,epigenetics,gene regulation,and aging[J].Biology(Basel),2019,8(2):30.
[11] EBELING P R.Vitamin D and bone health:epidemiologic studies[J].Bonekey Rep,2014,3:511.
[12] LIAO R X,YU M,JIANG Y,et al.Management of osteoporosis with calcitriol in elderly Chinese patients:a systematic review[J].Clin Interv Aging,2014,9:515-526.
[13] STOCKTON K A,MENGERSEN K,PARATZ J D,et al.Effect of vitamin D supplementation on muscle strength:a systematic review and meta-analysis[J].Osteoporos Int,2011,22(3):859-871.
[14] 林華,夏維波.雙膦酸鹽治療骨質(zhì)疏松癥的依從性管理和藥物假期選擇[J].中華骨質(zhì)疏松和骨礦鹽疾病雜志,2020,13(2):103-109.
[15] 邱貴興,裴福興,胡偵明,等.中國骨質(zhì)疏松性骨折診療指南(骨質(zhì)疏松性骨折診斷及治療原則)[J].中華骨與關(guān)節(jié)外科雜志,2015,8(5):371-374.
[16] 張祿鍇,馬劍雄,李風(fēng)波,等.雙膦酸鹽類藥物治療骨質(zhì)疏松癥的研究進展[J].中華老年骨科與康復(fù)電子雜志,2017,3(3):184-187.
[17] 余伯龍,李義凱.使用雙膦酸鹽類藥物的不良反應(yīng)[J].中國骨質(zhì)疏松雜志,2011,17(1):80-85.
[18] 萬金紅.唑來膦酸聯(lián)合鮭降鈣素治療老年性骨質(zhì)疏松的臨床效果[J].臨床合理用藥,2023,16(22):57-59.
[19] 劉云,羅曉婷,李崇,等.雌激素治療絕經(jīng)后骨質(zhì)疏松癥的研究進展[J].實用臨床醫(yī)學(xué),2020,21(10):91-96.
[20] 吳隆琦.雌激素替代治療絕經(jīng)后骨質(zhì)疏松癥引發(fā)的爭議[J].中國臨床康復(fù),2003,7(3):452.
[21] HIOKI T,MATSUSHIMA-NISHIWAKI R,TOKUDA H,et al.Selective estrogen receptor modulators,acting as agonists of estrogen receptor α in osteoblasts,reduce the TGF-β-induced synthesis of macrophage colony-stimulating factor via inhibition of JNK signaling pathway[J].Biomed Res,2022,43(6):211-221.
[22] 方巖,朱濤.絕經(jīng)后骨質(zhì)疏松癥的治療進展[J].中國骨質(zhì)疏松雜志,2019,25(8):1192-1200.
[23] JOHNSTON C B,DAGAR M.Osteoporosis in older adults[J].Med Clin North Am,2020,104(5):873-884.
[24] 馬寧,張浩沙強,王志剛,等.地舒單抗在骨質(zhì)疏松中的應(yīng)用研究進展[J].臨床醫(yī)學(xué)進展,2023,13(8):13454-13463.
[25] 羅健,李東文.唑來膦酸對比地舒單抗治療原發(fā)性骨質(zhì)疏松研究進展[J].醫(yī)學(xué)研究與戰(zhàn)創(chuàng)傷救治,2023,36(3):317-323.
[26] 杜桂平,李玉坤,李敏,等.地舒單抗和特立帕肽治療中國女性絕經(jīng)后骨質(zhì)疏松癥的成本-效用分析[J].中國藥房,2023,34(2):173-178.
[27] 張婧璇,王紅梅,孔令希,等.地舒單抗注射液對比唑來膦酸注射液治療絕經(jīng)后骨質(zhì)疏松癥的系統(tǒng)評價及成本-效果分析[J].中國醫(yī)院用藥評價與分析,2023,23(4):480-484.
[28] 谷營營,董偉.特立帕肽治療骨質(zhì)疏松癥的研究進展[J].醫(yī)藥導(dǎo)報,2022,41(9):1331-1334.
[29] 阿卜杜吾普爾·海比爾,阿里木江·玉素甫,買合木提·亞庫甫,等.特立帕肽和雙膦酸鹽治療絕經(jīng)后骨質(zhì)疏松性骨折有效及安全性的Meta分析[J].中國組織工程研究,2024,28(4):639-645.
[30] SILVERMAN S,MILLER P,SEBBA A,et al.The direct assessment of nonvertebral fractures in community experience(DANCE)study:2-year nonvertebral fragility fracture results[J].Osteoporos Int,2013,24(8):2309-2317.
[31] 黃國偉,毛偉,陳環(huán),等.骨質(zhì)疏松性椎體壓縮骨折術(shù)后使用特立帕肽療效的meta分析[J].中國醫(yī)藥科學(xué),2023,13(1):183-186.
[32] 楊寶峰,陳建國.藥理學(xué)[J].9版.北京:人民衛(wèi)生出版社,2018:355.
[33] 中華醫(yī)學(xué)會骨質(zhì)疏松和骨礦鹽疾病分會.男性骨質(zhì)疏松癥診療指南[J].中華骨質(zhì)疏松和骨礦鹽疾病雜志,2020,13(5):381-395.
[34] 張敏,郭雄.氟、鍶與骨質(zhì)疏松癥[J].國外醫(yī)學(xué)(醫(yī)學(xué)地理分冊),2005,26(2):53-55.
[35] 謝靜,陳佳,陳曦,等.羅莫珠單抗與安慰劑治療骨質(zhì)疏松癥療效與安全性的meta分析[J].重慶醫(yī)學(xué),2022,51(24):4258-4262.
[36] SAAG K G,PETERSEN J,BRANDI M L,et al.Romosozumab or alendronate for fracture prevention in women with osteoporosis[J].N Engl J Med,2017,377(15):1417-1427.
[37] PAIK J,SCOTT L J.Romosozumab:a review in postmenopausal osteoporosis[J].Drugs Aging,2020,37(11):845-855.
相似文獻(xiàn)/References:
[1]潘雄,劉其順,應(yīng)行,等.中藥聯(lián)合4步康復(fù)鍛煉法對骨質(zhì)疏松性椎體壓縮
骨折患者生存質(zhì)量的影響[J].中醫(yī)正骨,2015,27(04):65.
[2]宋永枝,陳雙玲.唑來膦酸靜脈滴注聯(lián)合鮭降鈣素肌肉注射治療
骨質(zhì)疏松性長骨骨折[J].中醫(yī)正骨,2016,28(01):70.
[3]吳鵬,王博,孔令成,等.強骨飲顆粒聯(lián)合阿侖膦酸鈉維D3片口服在原發(fā)性骨質(zhì)疏松性髖部骨折術(shù)后抗骨質(zhì)疏松治療中的應(yīng)用[J].中醫(yī)正骨,2016,28(05):16.
WU Peng,WANG Bo,KONG Lingcheng,et al.Oral application of Qiangguyin Keli(強骨飲顆粒)and alendronate sodium Vitamin D3 tablets in postoperative anti-osteoporosis treatment in patients with primary osteoporotic hip fractures[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2016,28(04):16.
[4]陳建德,樊曉琦,夏炳江,等.球囊擴張部位對椎體后凸成形術(shù)治療骨質(zhì)疏松性椎體壓縮骨折療效及安全性的影響[J].中醫(yī)正骨,2017,29(02):11.
CHEN Jiande,FAN Xiaoqi,XIA Bingjiang,et al.Influence of balloon dilation position on curative effect and safety of percutaneous kyphoplasty for treatment of osteoporotic vertebral compression fractures[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(04):11.
[5]史曉林,王健,王博,等.脆性骨折的防治進展[J].中醫(yī)正骨,2017,29(05):20.
[6]陳勍,劉鐘,陳文亮,等.股骨近端防旋髓內(nèi)釘固定聯(lián)合口服仙靈骨葆膠囊治療腎陽虛型骨質(zhì)疏松性股骨轉(zhuǎn)子間骨折[J].中醫(yī)正骨,2017,29(07):69.
[7]曾武,林曙峰,朱俊峰,等.女性骨質(zhì)疏松性橈骨遠(yuǎn)端骨折鎖定鋼板內(nèi)固定術(shù)后腕關(guān)節(jié)功能恢復(fù)的影響因素分析[J].中醫(yī)正骨,2017,29(08):39.
ZENG Wu,LIN Shufeng,ZHU Junfeng,et al.Analysis of factors influencing wrist function recovery after locking plate internal fixation for treatment of osteoporotic distal radius fractures in female[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(04):39.
[8]王威,馮興兵,王章富,等.口服藥物聯(lián)合手法松解及功能鍛煉治療神經(jīng)根型頸椎病的療效觀察及作用機制研究[J].中醫(yī)正骨,2017,29(09):70.
[9]齊英娜,王威,吳鑫杰,等.脊髓損傷后微循環(huán)的變化及微循環(huán)障礙的藥物治療進展[J].中醫(yī)正骨,2017,29(10):47.
[10]丁志清,顏峰,喻燦明,等.椎體后凸成形術(shù)后非典型骨水泥植入綜合征死亡1例[J].中醫(yī)正骨,2017,29(11):76.